<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02745184</url>
  </required_header>
  <id_info>
    <org_study_id>201602101</org_study_id>
    <nct_id>NCT02745184</nct_id>
  </id_info>
  <brief_title>Clinical Efficacy and Safety of Autologous Lung Stem Cell Transplantation in Patients With Idiopathic Pulmonary Fibrosis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai East Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regend Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai East Hospital</source>
  <brief_summary>
    <textblock>
      Idiopathic pulmonary fibrosis (IPF) is a chronic and ultimately fatal disease characterized
      by a progressive damage of lung structure and decline in lung function.This study intends to
      carry out an open, single-center, non-randomized, self control phase I clinical trial. During
      the treatment, lung stem cells will be isolated from patients' own bronchi and expanded in
      vitro. Cultured cells will be injected directly into the lesion by fiberoptic bronchoscopy
      after lavage. After twelve-month observation, the investigators will evaluate the safety and
      efficacy of the treatment by measuring the key clinical indicators.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in forced vital capacity (FVC)</measure>
    <time_frame>48 weeks</time_frame>
    <description>To evaluate changes in FVC from baseline to 48 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Forced expiratory volume in one second (FEV1)</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The differences of diffusing capacity of the lung for carbon monoxide (DLco)</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in 6 minute walk distance (6MWD)</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life quality: assessed by St. George respiratory questionnaire (SGRQ)</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea score according by Modified Medical Research Center(MMRC)</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>lung stem cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 10^6 (1 million)/Kg/person cells of clinical grade lung stem cells (LSCs)injected via fiberoptic bronchoscopy after fully lavage of the localized lesions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Lung stem cells</intervention_name>
    <description>Patients will receive 10^6 (1 million) /Kg/person cells of clinical grade lung stem cells (LSCs) injected via fiberoptic bronchoscopy after fully lavage of the localized lesions.</description>
    <arm_group_label>lung stem cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1)Written informed consent signed; 2)40&lt;Age&lt;=75 years; 3)Clinically diagnosed idiopathic
        pulmonary fibrosis(see 2011 guidance);

        Exclusion Criteria:

          1. Allergic to cell therapy;

          2. Patients with serious significant pulmonary infection need anti-infection treatment;

          3. Patients who has taken amiodarone which may cause pulmonary fibrosis in the past 3
             months;

          4. Patients with malignant tumor in the past 5 years;

          5. Participated in other clinical trials in the past 3 months;

          6. Patients with serious heart disease(NYHA class Ⅲ-Ⅳ), liver disease(ALT or AST 2 times
             above the upper level of normal value range), kidney disease(Cr above the upper level
             of normal value range);

          7. Pregnant or lactating women;

          8. The investigator assessed as inappropriate to participate in this clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tao Ren, M.D.</last_name>
    <email>rentao305@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wei Zuo, Ph.D.</last_name>
    <email>zuow@regend.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Regend Therapeutics</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215123</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Zuo, Ph.D.</last_name>
      <email>zuow@regend.cn</email>
    </contact>
    <contact_backup>
      <last_name>Ting Zhang, Ph.D.</last_name>
      <email>regendchina@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Wei Zuo, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ting Zhang, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yu Ma, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai East Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200123</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tao Ren, M.D.</last_name>
      <email>rentao305@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Lihua Bai, M.M.</last_name>
      <email>tongjiyixue@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Tao Ren, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Zuo W, Zhang T, Wu DZ, Guan SP, Liew AA, Yamamoto Y, Wang X, Lim SJ, Vincent M, Lessard M, Crum CP, Xian W, McKeon F. p63(+)Krt5(+) distal airway stem cells are essential for lung regeneration. Nature. 2015 Jan 29;517(7536):616-20. doi: 10.1038/nature13903. Epub 2014 Nov 12.</citation>
    <PMID>25383540</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2016</study_first_submitted>
  <study_first_submitted_qc>April 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2016</study_first_posted>
  <last_update_submitted>October 27, 2016</last_update_submitted>
  <last_update_submitted_qc>October 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai East Hospital</investigator_affiliation>
    <investigator_full_name>Wei Zuo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

